Navigation Links
Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
Date:10/28/2008


Ontario biotech companies work together on innovative bone protein

technology

TORONTO, Oct. 28 /PRNewswire/ - Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Dr. Cameron Clokie, President and CEO of Induce Biologics Inc. today announced a development partnership utilizing an innovative approach to the production and manufacture of selected growth factors for stimulating bone regeneration. Such growth factors are critical tools used in regenerative medicine, with particular applications in the regeneration of the skeleton.

Therapure will apply its experience and knowledge in cell culture and in the design and development of scaled-up biologic manufacturing processes to advance the initial research and development conducted by Induce. The technology is a result of over 10 years of research and development by the founders of Induce in the areas of bone regeneration and the development of growth factor containing bone grafts.

"Induce's technology is a tremendous example of the creativity and innovation that exists in Ontario," said Thomas Wellner. "We are very pleased that they have chosen Therapure Biopharma as their partner for the further development of this important new technology and we look forward to working with them to bring this product to a global market."

"Our technology was invented in Canada", said Cameron Clokie, "and we are excited to have found a company in Ontario that is capable of working with us to further develop this technology. We are pleased that Therapure Biopharma is as eager as we are to make this technology available to patients world-wide."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: http://www.therapurebio.com

About Induce Biologics Inc.:

Induce Biologics Inc was founded in 2008 to develop and commercialize technologies invented at the University of Toronto. Induce Biologics' goal is to utilize these technologies along with others being developed internally to create cost effective growth factor containing bone grafts for mammalian skeletal regeneration.


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
4. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
5. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
6. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 ... fragmented, states a research report by Transparency Market Research ... Inc., Amgen Inc., and AbbVie Inc., accounted for a ... The prominent players in this market are focusing aggressively ... product portfolio, which is likely to lead to market ...
(Date:3/22/2017)... 22, 2017 /PRNewswire/ - FACIT announced a seed ... "Propellon"), a start-up created by FACIT focused on ... investment, combined with non-dilutive capital, achieves a targeted ... funding enables Propellon to accelerate the nomination of ... financing and/or entering a strategic partnership for clinical ...
(Date:3/22/2017)... Pa. , March 22, 2017 /PRNewswire/ ... global independent provider of product and service ... today that it has acquired EPL Archives, ... supports customers across the entire regulated product ... archive sample, document storage and ancillary services. ...
(Date:3/22/2017)... Bahama (PRWEB) , ... March 21, 2017 , ... Okyanos ... educational seminar as part of their live events series, “Stem Cell Therapy: The Next ... cell facility under the 2013 Stem Cell Research and Therapy Act, Okyanos ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
Breaking Biology News(10 mins):